Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine

Area of Science:

• Immunology
• Dermatology
• Oncology

Background:

• Immunosuppression is a known risk factor for various cancers, particularly skin cancer in organ transplant recipients.
• Renal transplant recipients on immunosuppressive therapy, such as cyclosporine A, have a documented high risk of nonmelanocytic skin tumors.
• Malignant melanoma incidence is increasingly reported in immunosuppressed patient populations.

Observation:

• A 67-year-old male renal transplant recipient, maintained on azathioprine and prednisolone for 30 years, developed nodular malignant melanoma.
• The patient's renal graft function remained unaffected throughout the observation period.
• The patient succumbed to metastatic malignant melanoma three months post-diagnosis.

Findings:

• This case highlights the potential for azathioprine-based immunosuppression to be associated with malignant melanoma development.
• Despite long-term immunosuppression, renal graft function was preserved, indicating that immunosuppression for transplantation does not necessarily compromise graft viability in the short term.
• The rapid progression to metastatic disease underscores the aggressive nature of melanoma in this context.

Implications:

• Close dermatological surveillance is essential for all allograft recipients undergoing immunosuppressive therapy.
• Early recognition and diagnosis of skin malignancies in immunosuppressed patients can significantly reduce the risk of systemic metastasis and improve outcomes.
• This case emphasizes the need to consider melanoma surveillance strategies in renal transplant recipients, irrespective of the specific immunosuppressive agents used.